Overall prevalence of CKD in the U.S. adult general population was estimated to be 14.8%. But data on the prevalence of CKD among CVD population are limited.
Using the NHANES 2007-2014 data, we conducted a cross-sectional analysis of an adult sample with self-reported CVD (n=2325), aged ≥18 years, to assess prevalence of CKD in U.S. adults with CVD using KDIGO 2012 classification. Participants with CVD were identified based on self-reported personal interview data on a broad range of health conditions—congestive heart failure, coronary heart disease, angina, stroke, or heart attack. Appropriate sample weights were used to provide a national estimate.
Results of prevalence of CKD in U.S. adults with self-reported CVD are presented in Table 1. The prevalence of moderately to severely decreased renal impairment based on eGFR below 60 ml/min/1.73m2 was 24.9%: 14.1% with Stage 3a, 7.8% with Stage 3b, and 3.0% with Stage 4 or 5. The prevalence of mildly decreased renal impairment (stage 2, eGFR=60-90 ml/min/1.73m2) was 45.2%: 36.8% with UACR<30 mg/g (normal to mildly increased albuminuria), 7.4% with UACR≥ 30-300 mg/g (moderately increased albuminuria) and 1.1% with UACR >300mg/g (severely increased albuminuria).
T. Wang: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc.. Employee; Spouse/Partner; Janssen Pharmaceuticals, Inc.. Y. Xi: None. R.N. Lubwama: None. C. Koro: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; GlaxoSmithKline plc..